SBRT 2016

SBRT compared to MODERN CF-RT Randomized SPACE trial in 102 patients with stage I NSCLC

Tx

Dose

Margin

SBRT

3 x 22Gy

5-10mm

CF-RT

35 x 2Gy

20mm

Nyman ESTRO 2014

Tx

3a OS

FFP

Pneumonitis Esophagitis

SBRT

34%

61%

16%

9%

CF-RT

34%

57%

34%

32%

 No difference in oncological outcome  Smaller margins -> reduced toxicity

Stereotactic Radiotherapy / Matthias Guckenberger 13.06.2016

/